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Abstract 
The pathologic effects of type-2 diabetes on organ systems contribute to 
dyslipidemia, hypertension, cardiac and vascular remodeling, and kidney disease 
increasing the risk of heart attack, stroke (Cheng et al., 2012). Appropriate management 
of diabetes can delay onset of organ dysfunction, decreasing mortality, and improving 
quality of life (Nashar & Egan, 2014). The guidelines set by the American Diabetes 
Association (2016) indicates a therapeutic A1c value to be <6.5 percent in type-2 
diabetics. However, co-morbidities, such as renal failure and heart disease, as well as 
patient wishes play a key role in goals of treatment. The purpose of this clinical case 
study is to identify appropriate second-line therapy in addition to metformin in a type 2 
diabetic patient exhibiting clinical signs of progressive kidney disease. A case 
presentation of an adult female with type 2 diabetes and kidney disease will be addressed 
in this independent project. Lastly, a literature review and discussion of appropriate 
prescribing practices of some of the newer anti-diabetic medications for a patient with 
decreased renal function will then be conclude the case. 
Keywords: type-2 diabetes, pharmacological, treatments, chronic kidney disease, 
metabolic syndrome, pharmacotherapy 
Background  
In 2014 twenty-one million or 9.3 percent of Americans have been diagnosed 
with diabetes, and over eight million are believed to be living with this condition 
undiagnosed (CDC, 2014). According to the American Diabetes Association (ADA, 
2016) about 1.7 million people in the United States were newly diagnosed with diabetes 
contributing to heart, kidney, metabolic, and vascular dysfunction leading to increased 
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mortality. Also, about ninety percent of the diabetic population has type 2 diabetes also 
identified as insulin resistance (ADA, 2016). 
The American Diabetes Association (2016) and U.S Preventative Service Task 
Force (2015) guidelines recommend screening for people the age of 40 every three years 
through assessment of fasting plasma glucose >126mg/dL, or HgbA1c > 6.5%. Increased 
blood glucose and A1c levels are directly associated with decreased kidney function over 
time and diagnosed through albuminuria, and impaired glomerular-filtration rate (GFR) 
(ADA, 2014). Tight glucose control has several physiologic benefits including 
minimizing damage to arteries and preserving adequate renal blood flow (Nashar & 
Egan, 2014). Syndrome X was first noted in 1929, now labeled as metabolic syndrome 
originally was identified with clinical findings of three or more of the following five risk 
factors including abdominal obesity defined by waist circumference (men >102 cm; 
women 88 cm), triglycerides >150 mg/dL, low high-density lipoprotein (HDL) 
cholesterol levels (men >40 mg/dL; women >50 mg/dL), blood pressure >130/85 mmHg, 
and fasting glucose >100 mg (Nashar & Egan, 2014). In several studies reviewed by 
Nashar, and Egan, (2014) diagnosis of metabolic syndrome has been linked to increased 
mortality due to multiple organ dysfunction including complicating diagnosis and 
treatment. Therefore a multisystem approach is necessary to appropriately manage 
metabolic syndrome including clinical evaluation and intervention of blood glucose, 
cholesterol, blood pressure, and body-mass. As an example, Thomas & Atkins (2006) 
explains the role of how hypertension influences renal function. Blood sugar control is 
one of the parameters necessary for maximizing health in diabetes (Nashar & Egan, 
2014). 
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Primary care providers have an opportunity and obligation to recognize clinical 
findings of diabetes and metabolic syndrome and intervene to minimize the risk of organ 
damage due to elevated blood glucose. Screening for kidney function, dyslipidemia, 
hypertension, and diabetes as recommended by the U.S. Preventative Services Task Force 
(USPSTF, 2015), and the American Diabetes Association (ADA, 2016) encourages early 
diagnosis of individuals high-risk for chronic debilitating disease. Early diagnosis and 
intervention of type-2 diabetes aims at keeping blood glucose values as close to normal as 
possible without the patient having symptoms of hypoglycemia (ADA, 2016).  
The kidneys are responsible for elimination of a majority of drugs and it is the 
responsibility of all healthcare providers to recognize and make appropriate adjustments 
in medication therapy based on organ function (Liles, 2011).  Type 2 diabetes 
management choices should be individualized, taking into account patient comorbidities, 
and wishes when considering treatment (Tierney, 2012, p.2). Medication adjustments and 
close monitoring are required for several medications used to treat diabetes in the 
presence of renal disease, and some are not indicated to prescribe in the presence of renal 
disease (Fravel, et al., 2011). The elderly are also at risk for undesirable effects of 
diabetic management. Reduced dosage and careful monitoring are suggested in this 
population (Fravel, et al., 2011). Lack of renal dose adjustments of most medications can 
lead to undesired increased potency and increased toxicity which can be harmful to 
patients (Liles, 2011). 
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Case Report 
Chief Concern 
 Mrs. Jones presented to the clinic today after being referred by the clinic diabetic 
educator for evaluation of her diabetes. She was noted to be having pre-prandial blood 
sugar readings ranging from 150-200mg/dl. She is a new patient to me and is here today 
to establish with a primary care provider. Besides her elevated blood sugar, she has some 
mild exercise intolerance and has noticed minor lower-leg edema. She indicates her 
health has been otherwise good.   
Review of systems and past medical history 
 She is a sixty-five year-old retired teacher who appears younger than her stated 
age and does not appear to be in acute distress at the time of examination. She has been 
married for 40 years and her husband lives at home with her. They are both in good 
health. Her past medical history includes hypertension, type-2 diabetes, and 
hypercholesterolemia. She has had “elevated blood sugars” during previous annual visits 
and has started metformin therapy about six months ago and she indicates she felt like 
she was gaining control of her blood sugars. Recently her blood sugars have been slowly 
climbing. She understands her goal is to get her blood sugars down as close to 110-
140mg/dl however she has been unsuccessful. Mrs. Jones denies headaches, nausea, 
visual changes, fluctuations in weight, nausea or vomiting, palpitations, chest pain or 
heaviness, shortness of breath, pain in her abdomen, numbness or tingling in lower 
extremities, lesions on feet, sensory changes, and sexual dysfunction.  She has been 
following the suggestions of the dietician and diabetic educator and has not gained 
control of her blood sugars with three months of metformin therapy.  She regularly sees a 
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Dentist and an Ophthalmologist and she indicates no problems with her eyes or her teeth.  
She is post-menopausal and had a vaginal exam with a negative pap smear she believes 
was 2 years ago and denies any vaginal issues today. She denies any stressors at home or 
with family. She had a stent placed about two years ago.  She has had no other surgeries.  
She has not had a colonoscopy.  She is up to date on her immunizations including 
pneumonia, flu, tetanus, and shingles.  Indicates regular bowel movements and urinary 
patterns without pain, bleeding, or signs of infection.  
• Vital Signs:  BP 122/64mm/Hg, HR 64, BMI 25 
• Past Medical History 
o Uncontrolled type-2 diabetes on metformin therapy 
o Hypertension controlled with Lisinopril 20mg and Furosemide 20mg 
daily. 
o Hyperlipidemia, on Atorvastatin 20mg daily. 
o Coronary Artery Disease with history of stent placement. On Plavix 75mg 
daily. 
o Lower extremity edema and taking Furosemide 20mg daily 
• Allergies: Penicillin 
Physical Assessment 
• HEENT: Facial symmetry normal. Scalp clean and dry without lesions or 
irregularities. PERRLA, Fundoscopic eye exam shows normal red-reflex without 
lesions in posterior chamber. Tympanic membrane pearly-grey without redness or 
effusion, normal light reflex at 5 O’clock (right) and 7 O’clock (left) respectively. 
No prominent lymph nodes in submandibular, maxillary, axillary, suprasternal, 
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anterior or posterior cervical chains noted. Oral cavity normal moist intact 
mucous membranes without lesions. Teeth are in good condition. Thyroid 
palpated without noting abnormal or irregular lumps.   
• Skin: Color good throughout. Intact without cuts, scrapes, lesions, rashes, or 
discoloration. Minor bilateral non-pitting edema. 
• Heart/ vascular: Regular rate and rhythm without appreciating rubs, gallops, or 
murmurs. Equal regular pulses present in upper and lower extremities.  
• Lungs clear bilaterally with good air exchange. 
• Musculoskeletal: Good range of motion in all major joints without pain. Deep 
tendon reflexes normal patellar, and Achilles.  Determination of proprioception 
normal.  Lower extremity vibratory and filament test shows normal sensation, 
motion, and pulses bilaterally.  Skin intact without signs of injury or infection. 
Fasting labs ordered and reviewed this visit 
• CBC: WBC 8.92K/uL; RBC 5.04 M/uL; Hemoglobin 12.5g/dL;  
Platelets 351K/uL. 
• Basic Metabolic Panel: BUN 22mg/dL; Sodium 139mmol/L; Potassium 
3.9mmol/L; Chloride 102mmol/L; CO2 27.3mmol/L;  
Glucose 151; Creatinine 1.3mg/dL; Calcium 9.8mg/dL; GFR 49 (L); Albumin 
4g/dL; Alkaline Phosphate 88U/L; Total Protein 7.4g/dL. 
• Urinalysis: positive for protein <300mg/dL (otherwise normal findings). 
• Lipid panel: Triglycerides 231(H); Cholesterol 199; HDL 38(L);  
LDL 95; Cholesterol-HDL Ratio 3.5. 
• HgbA1c – 9.7mg/dl 
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Diagnosis and plan 
Uncontrolled type 2 diabetes mellitus. Reviewed HgbA1c level and blood 
sugars with her and discussed the consequences of poor control of her blood sugars such 
as heart, kidney, retinal and vascular disease. With her HgbA1c at 9.7 she will most 
likely need additional medication possibly insulin to reach goal of A1c <7.  Discussed 
options with Mrs. Jones included increasing Metformin, adding another anti-diabetic 
agent such as a second oral agent or insulin. It is unlikely increasing her HgbA1c to goal 
of 6.5-7 mg/dl will happen with increasing her metformin. Initiating a DPP-4 inhibitor 
would assist in lowering blood sugars through elimination in the urine. So stopping the 
metformin and adding Janumet 25/1000 BID would likely show improvement in the 
glucose levels. Continue visits to see the diabetic educator.  
Hypertriglyceridemia. Currently she is on 20mg of Atorvastatin. Discussed the 
possibility of recurrent coronary artery disease with elevated triglycerides and low-
normal HDL.  Mrs. Jones agrees to an increase her Atorvastatin to 40mg daily for 
cholesterol control. 
Stage 3a chronic renal disease with proteinuria. Discussed the findings of her 
lab work including protein in the urine and creatinine in the blood indicating moderate 
kidney disease. Repeat testing will need to be done to confirm chronic renal disease. I 
explained this is due to some of her conditions such as hypertension and diabetes 
damaging the small vessels in her kidneys and therefore protein is able to spill into the 
urine.  However, with continued blood pressure control and improved management of 
blood sugar I hope to see an improvement in this during her next appointment. If she is 
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still having moderate amounts of protein in her urine I will send her to Nephrology for a 
consult.    
Lower extremity edema. Non-pitting minor swelling bilateral lower extremities 
with mild increased shortness of breath with activity.  This still remains to be a concern 
for the client.  Offered to increase Lasix for a few days to see if this helps with the 
swelling and mild dyspnea with activity.  Will double Furosemide dosage to 40mg daily 
for 3days.  Then she is to return to original 20mg daily dosage.   
Follow-up. Will have her return to see me in four weeks for a basic metabolic 
panel and in three months for A1c, Basic Metabolic Panel, and Urinalysis. Discussed 
signs and symptoms of hypoglycemia, infection, and hyperglycemia. She should return to 
the clinic or call if she has any questions or concerns about her care.  
Literature Review 
Search stratagies 
 Review of the literature in support of the topic I electronically accessed the 
Harley E. French Library of the Health Sciences at the University of North Dakota, 
utilizing two search engines, the Cumulative Index to Nursing and Allied Health 
Literature (CINAHL) and PubMed. Literature search focused on management of type-2 
diabetes in the presence of chronic renal failure, and metabolic syndrome. “All text” 
search terms included “chronic kidney disease”, “type-2 diabetes”, “treatment”, 
“pharmacology”, and “metabolic syndrome”. 
 Filters applied to the search included “English”, “academic journals only” and 
“results within the last 8 years” elicited 223 articles matching the search. Filters 
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“pharmacotherapy” were then applied yielding 34 articles. Of these journal articles, ten 
were selected for critical analysis.   
Findings 
 There are several studies relating to the diagnoses and management of renal 
disease in diabetes and metabolic syndrome focusing on pharmacotherapies such as 
antihypertensive management, blood glucose control, statin therapy, and modifiable risk 
factors such as tobacco use, obesity, and dietary restrictions.  
 The following articles in this independent study will give insight into second-line 
treatment options in type-2 diabetes in the presence of chronic kidney disease. Mrs. Jones 
as presented in the clinical case presents with increased fasting blood glucose, A1c of 
9.7mg/dL and is in moderate renal impairment with marked proteinuria and elevated 
triglycerides. Drug selection will include consideration of the fact her A1c goal should be 
around 6.5-7.5mg/dL, and she is in stage 3a renal disease. Other considerations for drug 
selection will focus on lowering triglycerides, and increasing HDL cholesterol. Learning 
points of the literature review regarding diabetic treatment options for Mrs. Jones will 
follow each drug class.  
Glucagon-like peptide (GLP-1) receptor agonists / incretin therapy. These are 
also known as incretins have demonstrated weight reductions 4.4% so they are 
recommended in patients with a BMI > 35kg/m2, and offer cardiovascular benefits such 
as systolic blood pressure reduction (Tierney, 2012). GLP-1 antagonists are 
predominantly eliminated by filtration so patients with a GFR between 30-50ml/min need 
small dosage increases at 5 to 10mcg increments and monitoring for increased renal 
failure (Hamilton, 2012). GLP-1 receptor agonists such as exenatide and liraglutide, have 
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a significant effect over many therapies with an effect of lowering A1c 1.5%. and this 
drug requires minimal monitoring for renal function (Fleury, E. 2009). Liraglutide is 
designed to need minimal monitoring in the presence of renal disease. GLP-1 receptor 
agonists are resistant to the DPP-4 enzyme and provide direct stimulation of GLP-1 
receptors (Capaldi-Milfort, B. 2012). 
The GLP-1 receptor agonists Liraglutide would work in conjunction with 
metformin therapy well for Mrs. Jones due to the low chance of her renal dysfunction 
causing toxicity. The benefit of a reduction of 1.5% in her A1c would help, however she 
needs to come down at least two points in her A1c.  Increasing her metformin to 1000mg 
BID in collaboration with Liraglutide may be enough to bring her A1c to goal however 
her creatinine is borderline. 
Biguanides. Metformin is an anti-hyperglycemic agent that improves glucose 
tolerance in patients with type 2 diabetes and acts by lowering both basal and 
postprandial plasma glucose and is recommended for patients with a body mass of at least 
25Kg/meter squared (Hamilton, 2012). Biguanides decrease hepatic production of 
glucose, decrease intestinal uptake of glucose, and increase insulin sensitivity by 
enhancing peripheral glucose uptake and utilization and has a very low chance of 
producing hypoglycemia (Hamilton, 2012). Due to their effectiveness and minimal 
adverse side effects, Biguanides (metformin) are the mainstay of first line anti-diabetic 
treatment. Caution is recommended in patients with estimated glomerular filtration rates 
less than 45ml/min or serum creatinine > 1.4 (woman) and > 1.5 (men) because in 
significant renal impairment, there is a chance of lactic acidosis (0.03 cases per 1,000 
patient years) (Hamilton, 2012). Research by Shaw, Wilmot, & Kilpatrick, (2007) has 
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shown that metformin is safe in renal impairment as long at the estimated glomerular 
filtration rate is > 30 ml/min.  
Mrs. Jones was on this medication previously and she was taking 500mg BID. An 
increase in this medication would benefit her A1c and fasting glucose. Her creatinine 
being borderline elevated warrants careful watching of her renal functions but should be 
safe to increase to 1000mg twice daily.   
Thiazolidinediones. Pioglitazone is a thiazolidinedione and primarily excreted in 
feces via the liver and can be used in patients with CKD creatinine clearance >4 ml/min 
and has an effect of 1.5-2.1% decrease on A1c levels, however is associated with minor 
weight gain (Derosa, 2014).  Rosiglitazone, another thiazolidinedione, was removed by 
the FDA in 2013 due to the belief that it was associated with cardiovascular events such 
as heart attack and stroke (Derosa, 2014). It was reinstated in 2015 due to lack of findings 
linking the medication to possible cardiovascular side effects.  
Pioglitazone would be a good medication for her as it gives up to a 2% reduction 
in her A1c and can be used in renal disease without risk of toxicity because the 
medication is metabolized in the liver and excreted in the stool. Given the fact that her 
liver panel was the only lab that was perfect this may be a good choice as well. 
DPP-4 inhibitors / incretin therapy . DPP-4 inhibitors reduce glucose levels 
with a low risk of hypoglycemia DPP-4 inhibitors are generally “weight-neutral”, have a 
low risk of hypoglycemia, and come as a combined medication with metformin which 
makes them a preferred treatment plan often (Tierney, 2012). Sitagliptin and 
Vildagliptinn have significant side effects and cannot be administered with creatinine 
clearance <50ml/min (Hamilton, 2012). Saxagliptin on the other hand, can be used with a 
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creatinine clearance of 5-49ml/min at a reduced dosage of 2.5mg per day (Hamilton, 
2012) & (Plosker, 2014). All the DPP-4 inhibitors deliver a reduction in A1c of about 1.2 
-1.5% (Capaldi, 2012), 
DPP-4 inhibitor Saxagliptin would be the only medication in this class that would 
be appropriate for this patient as it can be given in the presence of impaired kidney 
function.  This is a medication provides a neutral weight and low risk of hypoglycemia, 
and would give a nice decrease in her A1c. 
Sulfonylureas. Sulfonylureas are primarily excreted in the liver however 
metabolites from the breakdown of the medication are excreted via the kidney (Liles, 
2011). Glyburide requires a creatinine clearance > 50ml/min, and Glimepiride requires a 
creatinine clearance > 22ml/min, and Glipizide requires no adjustment and could be 
utilized in hepatic impairment (Liles, 2011). Sulfonylureas are associated with weight 
gain (Capaldi, 2012). Fleury-Milfort, (2009) states incretin based sulfonylureas will 
deliver a 0.7% reduction in A1c values. 
Glimepiride or Glipzide would work in a patient with decreased renal disease and 
give a modest reduction to A1c value. This medication may not give enough of a 
decrease in A1c value at 0.7%. 
Insulin. Insulin is easily titrated and has excellent efficacy of reaching target A1c 
goals, however practitioners need to be aware that over half of the dosage of insulin is 
eliminated through the kidney making decreasing dosage necessary as renal function 
declines (Hamilton, 2012). Patients presenting with symptoms of hyperglycemia and A1c 
values >9.0% should initially use insulin therapy without delay because the consequences 
of uncontrolled hyperglycemia can be severe (Tierney, 2012). In the event of an acute 
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decrease in renal function the American College of Physicians recommends a 25% 
decrease in insulin dosage (Liles, 2011). 
Insulin would give adequate coverage and ability to drive her A1c to goal as 
desired. Insulin is very helpful as it can be utilized in renal disease with easy 
manipulation of the dosage. The dosage can be adjusted daily or even more frequently as 
needed to endure adequate control. As discussed earlier in the paper a majority of people 
would probably be put on multiple oral agents than start injections of insulin. However as 
Mrs. Jones’s renal disease progresses she will most likely need to start insulin. Having a 
brief discussion about the fact that she may need after some time will make the transition 
less traumatic.  
Many of these newer agents offer important advantages over the traditional 
therapies. Most of the new diabetic classes have a medication that is designed for clients 
with renal impairment. Having multiple options to prescribe in different patient 
presentations is helpful as a provider because it helps me tailor the drug therapy to the 
patient needs. To understand the risks and benefits of each of classes of drugs allows me 
as a practitioner to better educate and safely prescribe in the clinic setting. 
Conclusion 
 Metformin is clearly the first-line choice for type-2 diabetes management. 
Decisions for second-line treatment should include patient preference and desired 
HgbA1c goal. Options I would choose for this patient include additional oral therapy 
such as increasing her metformin and adding a DPP-4 inhibitor such as Januvia / 
Janumet. This medication would have the desired effect with minimal risk to renal 
function and her renal function is within guidelines to initiate this therapy. Discussion 
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about her renal impairment should be addressed with her during this and subsequent 
visits. The goal of diabetes management is to slow the progression of the disease in the 
microvascular compartment. With her creatinine at 1.4mg/dl she may experience 
increased renal failure and will need insulin to control her diabetes.  
Recommendations for practice 
 Many options available to clinicians for the treatment of type-2 diabetes and most 
of the classes of medications have a formulary that is applicable to patients with renal 
impairment. Therefore oral therapy should continue to be the first-line treatment for these 
patients. Options for providers are somewhat limited in patients with severe renal 
impairment and discussion of insulin therapy in the presence of stage 3b to 4 renal failure 
should be discussed with patients and utilized. The standard monitoring for changes in 
oral therapy is the HgbA1c and is most accurate if only drawn every three months. 
However, having the patient back in to have renal function studies evaluated may be 
needed every two to four weeks to ensure renal function is still adequate in patients with 
a creatinine approaching high-normal. A multisystem approach to managing diabetes is 
necessary for preservation of organ function including blood pressure, lipids, as well as 
blood-sugar and should be worked into the plan of care.  
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